Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New dystonic syndrome associated with butyrophenone therapy.

Literature DB >> 4115928

New dystonic syndrome associated with butyrophenone therapy.

K Ekbom, H Lindholm, L Ljungberg.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1972 PMID： 4115928 DOI： 10.1007/bf00316159

Source DB: PubMed Journal: Z Neurol ISSN： 0012-1037

× No keyword cloud information.

17 in total

1. Current status of major tranquilizers.

Authors: F J AYD
Journal: J Med Soc N J Date: 1960-01

2. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.

Authors: U Ungerstedt
Journal: Acta Physiol Scand Suppl Date: 1971

Review 3. Functions of the caudate nucleus.

Authors: I Divac
Journal: Acta Biol Exp (Warsz) Date: 1968

4. [Buronil and promazine therapy of patients with senile dementia. A double-blind study].

Authors: E Engstrand
Journal: Nord Psykiatr Tidsskr Date: 1967

5. Functional role of the nigro-neostriatal dopamine neurons.

Authors: N E Andén; A Dahlström; K Fuxe; K Larsson
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1966

6. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication.

Authors: R Hunter; W Blackwood; M C Smith; J N Cumings
Journal: J Neurol Sci Date: 1968 Sep-Oct Impact factor: 3.181

7. [Buronil (FG 5111)--a new butyrophenone derivative. A controlled clinical study on senile dementia and confusion].

Authors: H Simmelsgaard; M Mellergaard; A Vangtorp
Journal: Nord Med Date: 1967-02-16

8. The distribution of 35S-chlorpromazine in mice studied by whole body autoradiography.

Authors: S E Sjöstrand; G B Cassano; E Hansson
Journal: Arch Int Pharmacodyn Ther Date: 1965-07

9. Pharmacological and toxicological studies on gamma-(4-methylpiperidino)-p-fluorobutyrophenone (FG 5111)--a new neuroleptic agent.

Authors: J A Christensen; S Hernestam; J B Lassen; N Sterner
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1965

10. [Chronic dyskinesia due to treatment with thiethylperazine (Torecan)].

Authors: K Ekbom; T Ekstrand
Journal: Lakartidningen Date: 1972-01-12

22 in total

1. Clinical heterogeneity and underlying pathophysiological mechanisms of lateral flexion of the trunk in Parkinson's disease.

Authors: Eduardo de Pablo-Fernández; Alberto Villarejo-Galende
Journal: J Neurol Date: 2011-09-28 Impact factor: 4.849

2. Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms.

Authors: Alessandro Di Matteo; Alfonso Fasano; Giovanna Squintani; Lucia Ricciardi; Tommaso Bovi; Antonio Fiaschi; Paolo Barone; Michele Tinazzi
Journal: J Neurol Date: 2010-11-16 Impact factor: 4.849

New dystonic syndrome associated with butyrophenone therapy.

1. Current status of major tranquilizers.

2. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.

Review 3. Functions of the caudate nucleus.

4. [Buronil and promazine therapy of patients with senile dementia. A double-blind study].

5. Functional role of the nigro-neostriatal dopamine neurons.

6. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication.

7. [Buronil (FG 5111)--a new butyrophenone derivative. A controlled clinical study on senile dementia and confusion].

8. The distribution of 35S-chlorpromazine in mice studied by whole body autoradiography.

9. Pharmacological and toxicological studies on gamma-(4-methylpiperidino)-p-fluorobutyrophenone (FG 5111)--a new neuroleptic agent.

10. [Chronic dyskinesia due to treatment with thiethylperazine (Torecan)].

1. Clinical heterogeneity and underlying pathophysiological mechanisms of lateral flexion of the trunk in Parkinson's disease.

2. Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms.

3. Clozapine-associated Pisa syndrome: A rare type of tardive dystonia.

4. Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.

5. Pisa syndrome as presenting symptom of amyotrophic lateral sclerosis.

6. Management of Pisa syndrome with lateralized subthalamic stimulation.

Review 7. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management.

8. Pisa syndrome. Report of a case.

9. Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.

Review 10. Focal disorders of the spine with compensatory deformities: how to define them.